Answers are grounded in this paper and cite their sources.
Clinical outcomes of soft tissue sarcoma (STS) of the distal lower leg remain poorly characterized. We investigated the oncological and functional outcomes of it. We retrospectively reviewed 42 patients with distal lower leg STS who underwent surgery between 1996 and 2021. Functional outcomes were assessed by Musculoskeletal Tumor Society (MSTS) score, and oncological outcomes included local recurrence-free survival (LRFS), metastasis-free survival (MFS), and overall survival (OS). The median MSTS score was 26.5. In unadjusted comparisons, age ≥ 65 years, tumor size > 5 cm, bone reconstruction, and major nerve resection were associated with poorer function. Patients who underwent tendon reconstruction had MSTS scores and walking-support rates comparable to those of patients without tendon resection. The 5-year LRFS, MFS, and OS rates were 86%, 69%, and 73%, respectively. Tumor size > 5 cm was the only predictor of worse OS. Tendon reconstruction was associated with preserved postoperative function, whereas bone reconstruction was associated with lower functional scores in this cohort. Patients with larger tumor size (> 5 cm) need careful follow-up.
No takes yet. Share an insight, caveat, or question.
Nakata et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: